BioLine RX Other Income/Expense
The Other Income/Expense (Net) of BioLine RX (BLRX.TA) as of Sep 27, 2026 is 18.39 M USD. In the previous year, Other Income/Expense (Net) was -10.84 M USD — a change of -269.59% (higher).
Get this data via API
Financial Data API
Other Income/Expense
18.39 MUSD
YoY
-269.59%
Last updated:
The BioLine RX Other Income/Expense history
3 Years
10 Years
25 Years
Max
| YEAR | Other Income/Expense | YoY |
|---|---|---|
| 18.39 MUSD | -269.59% | |
| -10.84 MUSD | -292.13% | |
| 5.64 MUSD | -404.75% | |
| -1.85 MUSD | -67.51% | |
| -5.70 MUSD | +1,056.39% | |
| -493,000.00USD | -470.68% | |
| 133,000.00USD | -186.36% | |
| -154,000.00USD | +2,100.00% | |
| -7,000.00USD | -105.07% | |
| 138,000.00USD | -133.66% | |
| -410,000.00USD | — |
BioLine RX Stock analysis
Frequently Asked Questions about BioLine RX stock
Other Income/Expense (Net) of BioLine RX is 18.39 M USD in 2026.
Other Income/Expense (Net) of BioLine RX changed from -10.84 M USD to 18.39 M USD, representing a -269.59% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Other Income/Expense (Net) BioLine RX since 2006 – with annual values, charts, and detailed analysis.
Other income and expense includes non-operating items such as gains/losses on investments, foreign exchange, and other non-core activities.
Other Income/Expense (Net)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Other Income/Expense (Net)'s BioLine RX historically and in real time.
Income Statement — BioLine RX
All Key Metrics — BioLine RX
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth